Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.23.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:        
Contract Revenue $ 1,063 $ 1,096 $ 1,063
Costs and expenses:        
Research and development 3,559 4,127 7,530 9,105
General and administrative 2,600 2,861 5,311 5,606
Total costs and expenses 6,159 6,988 12,841 14,711
Loss from operations (6,159) (5,925) (11,745) (13,648)
Sale of New Jersey net operating losses & tax credits 1,734
Other income, net 99 2 172 13
Net loss $ (6,060) $ (5,923) $ (11,573) $ (11,901)
Net loss per share - basic $ (0.03) $ (0.03) $ (0.05) $ (0.06)
Net loss per share - diluted $ (0.03) $ (0.03) $ (0.05) $ (0.06)
Weighted average common shares outstanding - basic 217,264,526 216,864,526 217,264,526 216,755,261
Weighted average common shares outstanding - diluted 217,264,526 216,864,526 217,264,526 216,755,261
Other comprehensive gain/(loss), net of tax        
Unrealized gain/(loss) on securities available-for-sale $ 81 $ (125) $ 310 $ (609)
Other comprehensive gain/(loss), net of tax 81 (125) 310 (609)
Comprehensive loss $ (5,979) $ (6,048) $ (11,263) $ (12,510)